Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

IGI Laboratories Names Jason Grenfell-Gardner CEO

RELATED NEWS
Trade IG now with 

IGI Laboratories, Inc. (IG: Quote) Monday said Jason Grenfell-Gardner has been appointed President and Chief Executive Officer of the firm, effective July 30.

Jason Grenfell-Gardner brings significant experience in the pharmaceutical industry, with a special focus on generics. He was most recently the Senior Vice President of Sales and Marketing for West-Ward Pharmaceuticals, the US Subsidiary of Hikma Pharmaceuticals.

Jason had a key role in the senior management team there, which grew the business from just over $100 million in 2008 to over $300 million in 2011. He strengthened West-Ward's presence in the sterile injectable space through the acquisition of Baxter International, Inc.'s multisource injectable business in 2011.

Jason originally joined Hikma Pharmaceuticals to lead its initial public offering in 2004, and later headed its business development efforts.

Click here to receive FREE breaking news email alerts for IGI, Laboratories, Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Russia's central bank decided to lift its key rate unexpectedly on Friday as geopolitical tensions increased risks of inflation amid rising threats to growth. The Board of Directors of Bank of Russia raised the key rate by 50 basis points to 8 percent. The bank was widely expected to leave rates unchanged. The rate has been hiked by a cumulative 250 basis points since February. Germany consumer confidence is set to improve further in August to the strongest level since December 2006 despite escalating geopolitical tensions in Israel and Ukraine, data from market research group GfK showed Friday. The forward-looking consumer sentiment index rose to 9 in August, while it was expected to remain unchanged at 8.9. This was the highest value recorded since December 2006. Amazon.com, Inc. said Thursday that its second quarter loss widened from last year, as operating expenses outpaced revenue growth amid heavy spending on new technology and contents. The company's quarterly loss per share was also wider than what analysts expected, but is quarterly sales came in line with analysts' forecast. The company also forecast an operating loss for the current quarter.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.